Stifel analyst Annabel Samimy downgraded Prometheus to Hold from Buy with a price target of $200, up from $155, after the company agreed to be acquired by Merck (MRK) for $200 per share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXDX:
- Prometheus downgraded to Neutral from Buy at BTIG
- Merck Acquiring Prometheus Biosciences
- Merck acquires Prometheus Biosciences for $200 per share
- Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
- Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference